抑制CDK4/6增强了SHP2抑制剂的有效性,并且在恶性外围神经膜瘤中取决于RB功能
Jiawan Wang1, Ana Calizo1, Lindy Zhang1
1Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Department of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
将SHP2抑制剂与CDK4/6抑制剂结合起来,对治疗恶性外围神经膜瘤 (MPNSTs) 显示出有前途. 这种双药方法增强了抗瘤活性,并支持MPNST和NF1驱动癌症的临床进展.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 恶性外围神经膜瘤 (MPNSTs) 是具有不良预后的侵袭性瘤.
- 有限有效的治疗选择需要新的治疗策略MPNSTs.
研究的目的:
- 研究MPNST中SHP2抑制的抗增殖作用.
- 评估将SHP2抑制剂 (TNO155) 与CDK4/6抑制剂 (CDK4/6i) 结合以克服耐药性和增强抗瘤活性的疗效.
主要方法:
- 使用SHP2抑制剂TNO155.5的PTPN11的遗传衰竭和药理抑制.
- 评估信号通路,包括RB功能,以应对SHP2抑制.
- 在体外和体内MPNST模型中使用TNO155和CDK4/6抑制剂进行组合疗法研究.
主要成果:
- 在MPNST模型中,SHP2抑制 (TNO155) 证明了抗增殖作用.
- 对TNO155的耐药性部分由减少的RB功能介导.
- TNO155和CDK4/6i的组合协同增强了抗瘤活性,抑制了细胞循环进展,并减少了细胞亡抑制剂蛋白质,从而导致更持久的反应.
结论:
- SHP2和CDK4/6抑制剂的组合为MPNSTs提供了一个强大的治疗策略.
- 这种组合策略显示了MPNST和其他NF1驱动瘤的临床进展潜力.
更多相关视频
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
相关概念视频
Inhibition of Cdk Activity
Abnormal Proliferation
Negative Regulator Molecules
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
